1. Scrip
  2. >>Focus On Asia

Dr Reddy’s On Semaglutide Canada Opportunity: “We have a good chance”

CEO shares early assessment of Trump 2.0

 
• By Anju Ghangurde

Dr Reddy’s hopes to be the “first one in the pack”, when Ozempic loses patent cover next year in markets like Canada, where the semaglutide opportunity is projected at $2bn. Openings for the product in 80 smaller markets also loom, it said, but the GLP-1 agonist won’t ‘replace’ generic Revlimid and all business levers will have to grow.

Opportunity
Dr Reddy's shares outlook for semaglutide (Shutterstock)

Dr Reddy’s senior management took on a barrage of questions on the emerging opportunity for semaglutide in markets like Canada at the firm’s earnings call for the third quarter of fiscal 2025, signaling how things may shape there when the GLP-I agonist goes off patent next year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia